Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention

Trial Profile

Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Ticagrelor (Primary) ; Prasugrel
  • Indications Coronary thrombosis
  • Focus Therapeutic Use
  • Acronyms ISAR ADAPT-PF
  • Most Recent Events

    • 31 Oct 2013 Planned end date changed from 15 May 2012 to 1 May 2014 as reported by ClinicalTrials.gov.
    • 19 Oct 2011 New trial record
    • 18 Oct 2011 Additional trial centre and trial investigators identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top